Deep brain stimulation is effective in pediatric patients with GNAO1 associated severe hyperkinesia

Archive ouverte

Koy, Anne | Cirak, Sebahattin | Gonzalez, Victoria | Becker, Kerstin | Roujeau, Thomas | Milesi, Christophe | Baleine, Julien | Cambonie, Gilles | Boularan, Alain | Greco, Frederic | Perrigault, Pierre-Francois | Cances, Claude | Dorison, Nathalie | Doummar, Diane | Roubertie, Agathe | Béroud, Christophe | Koerber, Friederike | Stueve, Burkhard | Waltz, Stephan | Mignot, Cyril | Nava, Caroline | Maarouf, Mohammad | Coubes, Philippe | Cif, Laura

Edité par CCSD ; Elsevier -

International audience. Background: Exacerbation of hyperkinesia is a life-threatening complication of dyskinetic movement disorders, which can lead to multi-organ failure and even to death. GNAO1 has been recently identified to be involved in the pathogenesis of early infantile epileptic encephalopathy and movement disorders. Patients with GNAO1 mutations can present with a severe, progressive hyperkinetic movement disorder with prolonged life-threatening exacerbations, which are refractory to most anti-dystonic medication. Objective: The objective was to investigate the evolution of symptoms and the response to deep brain stimulation of the globus pallidus internus (GPi-DBS) in patients with different GNAO1 mutations. Methods: We report six patients presenting with global motor retardation, reduced muscle tone and recurrent episodes of severe, life-threatening hyperkinesia with dystonia, choreoathetosis, and ballism since early childhood. Five of them underwent GPi-DBS. Results: The genetic workup revealed mutations in GNAO1 for all six patients. These encompass a new splice site mutation (c.723 + 1G > T) in patient 1, a new missense mutation (c.610G > C; p.Gly204Arg) in patient 2, a heterozygous mutation (c.625 > T; p.Arg209Cys) in patients 3 and 4, and a heterozygous mutation (c.709G > A; p.Glu237Lys) in patients 5 and 6. By intervention with GPi-DBS the severe paroxysmal hyperkinetic exacerbations could be stopped in five patients. One patient is still under evaluation for neuromodulation. Conclusion In complex movement disorders of unsolved etiology clinical WES can rapidly streamline pathogenic genes. We identified two novel GNAO1 mutations. GPi-DBS can be an effective and life-saving treatment option for patients with GNAO1 mutations and has to be considered early.

Consulter en ligne

Suggestions

Du même auteur

KMT2B -related disorders: expansion of the phenotypic spectrum and long-term efficacy of deep brain stimulation

Archive ouverte | Cif, Laura | CCSD

International audience. Abstract Heterozygous mutations in KMT2B are associated with an early-onset, progressive and often complex dystonia (DYT28). Key characteristics of typical disease include focal motor feature...

Deep brain stimulation treated dystonia-trajectory via status dystonicus

Archive ouverte | Nerrant, Elodie | CCSD

International audience. BACKGROUND: Status dystonicus (SD) is a life-threatening condition. OBJECTIVE AND METHODS: In a dystonia cohort who developed status dystonicus, we analyzed demographics, background dystonia ...

Intraputaminal Gene Delivery in Two Patients with Aromatic L‐Amino Acid Decarboxylase Deficiency

Archive ouverte | François-Heude, Marie‐céline | CCSD

International audience. Background: Aromatic l-amino acid decarboxylase deficiency (AADCD) is a rare, early-onset, dyskinetic encephalopathy mostly reflecting a defective synthesis of brain dopamine and serotonin. I...

Chargement des enrichissements...